Neuraxis

Neuraxis Assets per Share

The Total Assets per Share of Neuraxis (NRXS) as of Nov 22, 2026 is 0.60 USD. In the previous year, Total Assets per Share was 0.45 USD — a change of 34.61% (higher).

Assets per Share

0.60USD

YoY

34.61%

Last updated:

Total Assets per Share of Neuraxis is 2025 0.60 USD. Total Assets per Share of Neuraxis was 2024 0.45 USD. It decreases by 34.61% higher compared to the previous year.

The Neuraxis Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2020
0.26 USD
Jan 1, 2021
0.07 USD
Jan 1, 2022
0.14 USD
Jan 1, 2023
0.05 USD
Jan 1, 2024
0.45 USD
Jan 1, 2025
0.60 USD
The Neuraxis Assets per Share history
YEARAssets per ShareYoY
0.60USD+34.61%
0.45USD+833.78%
0.05USD-65.59%
0.14USD+94.70%
0.07USD-72.74%
0.26USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

Total Assets per Share of Neuraxis is 0.60 USD in 2025.

Total Assets per Share of Neuraxis changed from 0.45 USD to 0.60 USD, representing a 34.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Neuraxis since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Neuraxis

All Key Metrics — Neuraxis